CN102241722B - A kind of purification process synthesizing progesterone receptor modulator gifted zafirlukast - Google Patents
A kind of purification process synthesizing progesterone receptor modulator gifted zafirlukast Download PDFInfo
- Publication number
- CN102241722B CN102241722B CN201010169772.XA CN201010169772A CN102241722B CN 102241722 B CN102241722 B CN 102241722B CN 201010169772 A CN201010169772 A CN 201010169772A CN 102241722 B CN102241722 B CN 102241722B
- Authority
- CN
- China
- Prior art keywords
- gifted
- zafirlukast
- receptor modulator
- progesterone receptor
- purification process
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Abstract
The invention provides the purification process that a kind of progesterone receptor modulator ulipristal acetate is new.The method can be removed various impurity fast and obtain high purity ulipristal acetate, and method is easy and simple to handle, and yield is high, and suitability for industrialized is produced.
Description
Technical field
What the present invention relates to is a kind of progesterone receptor modulator ulipristal acetate (ulipristalacetate), i.e. 17 α-acetoxyl group-11 β-[4-(N, N-dimethylamino)-phenyl] purification process that-19-norpregna-4,9-diene-3,20-diketone is new.
Technical background
Ulipristal acetate (ulipristalacetate, formula I) is a kind of progesterone receptor modulator, tool PgR antagonism and PAA.This medicine is developed by HRA drugmaker, obtains EU Committee's approval in May, 2009, as the emergency contraception used in after the sexual intercourse of women's unprotect or contraceptive failure 5 days.
About ulipristal acetate medicine wherein a kind of typical synthetic method at United States Patent (USP) 5,929, open in 262.Be described to a kind of product in yellow crystals form with the final product that the method described in described United States Patent (USP) 5,929,262 embodiment 7 obtains, fusing point is between 183 and 185 DEG C.The existence of described yellow color shows to there is impurity, mainly phenolic compound.
PCT patent 2004/065405 discloses ulipristal acetate preparation method, and it is by the recrystallization to key intermediate Virahol half solvate, obtains not containing the ulipristal acetate crystal of solvation.The final product purity obtained in this way is wayward, and the intermediate gifted zafirlukast do not reacted completely and demethylation gifted zafirlukast remain larger.
Summary of the invention
The invention provides and a kind ofly simply can remove the method that impurity obtains high purity ulipristal acetate crystal.
Be specially:
Crude product gifted zafirlukast, by silica column purification, removes the impurity (intermediate gifted zafirlukast and demethylation gifted zafirlukast etc.) that Polarity comparision is large.Remove the impurity (mainly phenolic compound) of some low polarity again with ethyl acetate and sherwood oil recrystallization, the ratio of ethyl acetate and sherwood oil is 1: 1 ~ 1: 5.Use ethanol and water crystallization again, remove residual solvent.The ratio of second alcohol and water is 1: 1 ~ 1: 2.
The advantage of the method is:
1) silica column purification is adopted to remove intermediate gifted zafirlukast and demethylation gifted zafirlukast (these impurity can not be removed clean by other existing published methods, such as with ethanol/water or Virahol) fast;
2) impurity of some low polarity is removed with ethyl acetate and sherwood oil recrystallization;
3) can remove with ethanol/water crystallization and remain in ethyl acetate and sherwood oil in crystal;
4) simple, be applicable to industrialized production.
Embodiment
Embodiment 1
1) ulipristal acetate crude product 40g 60g silica gel (1.5 times) dense dry loading, cross silica gel and lean on 800g silica gel (200-300 order silica gel, 20 times of weight consumptions), with methylene dichloride: acetone=20: 1 wash-out, collect product, concentrate after doing and namely obtain desired product 35g.
2) concentrated dry rear 35g ulipristal acetate ethyl acetate 105ml dissolves, and adds 315ml sherwood oil, stirs one hour.Subsequent filtration.Solid sherwood oil: ethyl acetate=5: the mixing solutions 50 milliliters of 1 washes twice.Decompression drying.Obtain white solid powder 32 grams.
3) white solid powder 32 grams is dissolved in 300ml dehydrated alcohol, and control temperature (70 ~ 75 DEG C) under reflux conditions adds water 360ml, leaves standstill and drops to room temperature.Crystal filters, and 40 DEG C of decompression dryings obtain final product 28 grams.
Embodiment 2
1) the dense dry loading of ulipristal acetate crude product 80g 120g silica gel, cross silica gel and lean on 2400g silica gel (200-300 order silica gel, 30 times of weight consumptions), with methylene dichloride: acetone=10: 1 wash-out, collect product, concentrate after doing and namely obtain desired product 70g.
2) concentrated dry rear 70g ulipristal acetate ethyl acetate 210ml dissolves, and adds 210ml sherwood oil, stirs one hour.Subsequent filtration.Solid sherwood oil: ethyl acetate=1: the mixing solutions 100 milliliters of 1 washes twice.Decompression drying.Obtain white solid powder 58 grams.
3) white solid powder 58 grams is dissolved in 500ml dehydrated alcohol, and control temperature (70 ~ 75 DEG C) under reflux conditions adds water 500ml, leaves standstill and drops to room temperature.Crystal filters, and 40 DEG C of decompression dryings obtain final product 52 grams.
Embodiment 3
1) ulipristal acetate crude product 60g 100g silica gel (1.5 times) dense dry loading, cross silica gel and lean on 900g silica gel (200-300 order silica gel), with methylene dichloride: acetone=15: 1 wash-out, collect product, concentrated dry after namely obtain desired product 52g.
2) concentrated dry rear 52g ulipristal acetate ethyl acetate 156ml dissolves, and adds 780ml sherwood oil, stirs one and a half hours.Subsequent filtration.Solid sherwood oil: ethyl acetate=5: the mixing solutions 60 milliliters of 1 washes twice.Decompression drying.Obtain white solid powder 49 grams.
3) white solid powder 49 grams is dissolved in 300ml dehydrated alcohol, and control temperature (70 ~ 75 DEG C) under reflux conditions adds water 450ml, leaves standstill and drops to room temperature.Crystal filters, and 40 DEG C of decompression dryings obtain final product 47 grams.
Embodiment 4
Get US5,929, each foreign matter content of products measure of 262 embodiments 7, WO2004/065405 embodiment 3 and the embodiment of the present invention 1 gained.
The each foreign matter content of product (phenolic compound, intermediate gifted zafirlukast, demethylation gifted zafirlukast) of visible employing process for purification of the present invention gained is all starkly lower than US5,929,262 and WO2004/065405 in product.
Claims (3)
1. the industrialized purification method of a ulipristal acetate (I):
It is characterized in that the method first uses ethyl acetate and sherwood oil crystallization again with silica column purification, finally use ethanol and water crystallization desolventizing, described ethyl acetate and sherwood oil ratio are 1:1 ~ 1:5.
2. method according to claim 1, is characterized in that described silica column purification solution is methylene dichloride and acetone.
3., according to the method for claim 1 ~ 2, it is characterized in that the ratio of described second alcohol and water is 1:1 ~ 1:2.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201010169772.XA CN102241722B (en) | 2010-05-12 | 2010-05-12 | A kind of purification process synthesizing progesterone receptor modulator gifted zafirlukast |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201010169772.XA CN102241722B (en) | 2010-05-12 | 2010-05-12 | A kind of purification process synthesizing progesterone receptor modulator gifted zafirlukast |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102241722A CN102241722A (en) | 2011-11-16 |
| CN102241722B true CN102241722B (en) | 2015-11-25 |
Family
ID=44959993
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201010169772.XA Active CN102241722B (en) | 2010-05-12 | 2010-05-12 | A kind of purification process synthesizing progesterone receptor modulator gifted zafirlukast |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102241722B (en) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102295674B (en) * | 2011-07-14 | 2013-04-10 | 四川大学 | Method of acquiring high-purity 17 alpha-acetoxy-11 beta-(4-N, N-dimethylaminophenyl)-19-norpregna-4, 9-diene-3, 20-dione |
| CN102344478B (en) * | 2011-07-22 | 2013-08-07 | 上海希迈医药科技有限公司 | Crystal of 17 alpha-acetoxyl group-11 beta-(4-N, N-dimethylamino phenyl)-19-norpregna-4, 9- diene-3, 20- ketone and preparation method thereof |
| CN102321141B (en) * | 2011-07-22 | 2013-05-15 | 上海希迈医药科技有限公司 | Amorphous substance of 17alpha-acetoxy-11beta-(4-N,N-dimethylaminophenyl)-19-norpregn-4,9-diene-3,20-diketone and preparation method thereof |
| CN103755765B (en) * | 2012-04-17 | 2018-01-02 | 常州市第四制药厂有限公司 | Polymorphic of CDB-2914 and preparation method thereof |
| CN102887931B (en) * | 2012-07-07 | 2015-04-15 | 山东诚创医药技术开发有限公司 | Ulipristal acetate crystals and preparation method thereof |
| CN104418930B (en) * | 2013-08-23 | 2018-01-12 | 四川海思科制药有限公司 | A kind of high-purity CDB-2914 |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5929262A (en) * | 1995-03-30 | 1999-07-27 | The United States Of America As Represented By The Department Of Health And Human Services | Method for preparing 17α-acetoxy-11β-(4-N, N-dimethylaminophyl)-19-Norpregna-4,9-diene-3, 20-dione, intermediates useful in the method, and methods for the preparation of such intermediates |
| CN1298409A (en) * | 1998-03-06 | 2001-06-06 | 研究三角协会 | 20-keto-11&beta, -arylsteroids and their derivatives having agonist or antagonist hormonal properties |
| WO2004078709A2 (en) * | 2003-02-28 | 2004-09-16 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | METHOD FOR PREPARING 17 α-ACETOXY-11β-(4-N,N-DIMETHYLAMINOPHENYL)-19-NORPREGNA-4,9-DIENE-3,20-DIONE, INTERMEDIATES THEREOF, AND METHODS FOR THE PREPARATION OF SUCH INTERMEDIATES |
| CN1753905A (en) * | 2003-01-22 | 2006-03-29 | 克利斯托制药股份有限公司 | Method of obtaining 17alpha-acetoxy-11beta-(4-n,n-dimethylaminophenyl)-19-norpregna-4,9-diene-3,20-dione |
| CN101466723A (en) * | 2006-06-14 | 2009-06-24 | 吉瑞工厂 | Industrial process for the synthesis of 17a-acetoxy-11ss-[4-(n,n-dimethyl-amino)- phenyl]-19-norpregna-4,9-diene-3,20-dione and new intermediates of the process |
-
2010
- 2010-05-12 CN CN201010169772.XA patent/CN102241722B/en active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5929262A (en) * | 1995-03-30 | 1999-07-27 | The United States Of America As Represented By The Department Of Health And Human Services | Method for preparing 17α-acetoxy-11β-(4-N, N-dimethylaminophyl)-19-Norpregna-4,9-diene-3, 20-dione, intermediates useful in the method, and methods for the preparation of such intermediates |
| CN1298409A (en) * | 1998-03-06 | 2001-06-06 | 研究三角协会 | 20-keto-11&beta, -arylsteroids and their derivatives having agonist or antagonist hormonal properties |
| CN1753905A (en) * | 2003-01-22 | 2006-03-29 | 克利斯托制药股份有限公司 | Method of obtaining 17alpha-acetoxy-11beta-(4-n,n-dimethylaminophenyl)-19-norpregna-4,9-diene-3,20-dione |
| WO2004078709A2 (en) * | 2003-02-28 | 2004-09-16 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | METHOD FOR PREPARING 17 α-ACETOXY-11β-(4-N,N-DIMETHYLAMINOPHENYL)-19-NORPREGNA-4,9-DIENE-3,20-DIONE, INTERMEDIATES THEREOF, AND METHODS FOR THE PREPARATION OF SUCH INTERMEDIATES |
| CN101466723A (en) * | 2006-06-14 | 2009-06-24 | 吉瑞工厂 | Industrial process for the synthesis of 17a-acetoxy-11ss-[4-(n,n-dimethyl-amino)- phenyl]-19-norpregna-4,9-diene-3,20-dione and new intermediates of the process |
Non-Patent Citations (1)
| Title |
|---|
| A practical large-scale synthesis of 17a-acetoxy-11b-(4-N,N-dimethylaminophenyl)-19-norpregna-4,9-diene-3,20-dione(CDB-2914);Pemmaraju N. Rao 等;《Steroids》;20000731;第65卷(第7期);第395-400页，尤其第399页化合物8的制备 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102241722A (en) | 2011-11-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102241722B (en) | A kind of purification process synthesizing progesterone receptor modulator gifted zafirlukast | |
| CN104072549B (en) | The production technique of Gastrodine | |
| CN102372760A (en) | Synthesis method of progesterone receptor regulating agent ulipristal | |
| ITPG20120030A1 (en) | HYBRID INORGANIC RESVERATROL | |
| CN102887817A (en) | Novel method for synthesizing 2,3,4,5,6-pentafluorophenol | |
| CN102911022A (en) | Method for artificially synthesizing natural curcumin compound | |
| CN112441952B (en) | Cannabidiol-3-sulfonic acid, preparation method and application thereof, and cannabidiol derivative | |
| CN104744543A (en) | Preparation method of pregnenolone phosphate derivatives and their salts | |
| CN102453011A (en) | Preparation method of high-purity naringenin | |
| CN102206208A (en) | Preparation method for olmensartan medoxomil with low-level impurity | |
| CN104326954B (en) | A kind of synthetic method of Fudosteine | |
| CN102558256B (en) | Method for separation and preparation of tenuifolin from polygala tenuifolia | |
| CN104402815B (en) | Control method of piperaquine phosphate impurity | |
| CN101239947B (en) | Method for preparing cryptotanshinone | |
| CN103193632B (en) | Synthesis method of salicylic acid imidazole | |
| CN103638871B (en) | The tensio-active agent containing double connection group prepared with N, N ˊ-dimethyl piperazidine and preparation method | |
| CN102350091B (en) | Method for separating aliphatic acid plant sterol ester crude product by composite extractant | |
| CN102060756B (en) | Method for preparing sodium picosulfate monohydrate | |
| CN102924417A (en) | 4-(chloromethyl)-7-hydroxy coumarin compound and preparation method thereof | |
| CN105111758B (en) | Asphalt high-moduluss agent and preparation method thereof and bituminous composition | |
| CN104151192A (en) | Improved method of preparation technology of mildronate intermediate 3-(2,2,2-trimethylhydrazine) methyl acrylate methyl sulfate | |
| CN105585524B (en) | A kind of method that Menglusitena is prepared by montelukast acid | |
| CN104230808A (en) | Amorphous ivabradine hydrochloride, and preparation method and application thereof | |
| CN108329310A (en) | The preparation method of fibrauretine | |
| CN103772479A (en) | Method for preparing tanshinone IIA sodium sulfonate by using tanshinone crude extract |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |